EP2456350A1 - Dispositif de traitement des acouphènes - Google Patents
Dispositif de traitement des acouphènesInfo
- Publication number
- EP2456350A1 EP2456350A1 EP10730812A EP10730812A EP2456350A1 EP 2456350 A1 EP2456350 A1 EP 2456350A1 EP 10730812 A EP10730812 A EP 10730812A EP 10730812 A EP10730812 A EP 10730812A EP 2456350 A1 EP2456350 A1 EP 2456350A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- frequency
- eeg
- tinnitus
- therapy
- alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000009205 Tinnitus Diseases 0.000 claims abstract description 61
- 231100000886 tinnitus Toxicity 0.000 claims abstract description 56
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 42
- 230000005672 electromagnetic field Effects 0.000 claims abstract description 4
- 238000000354 decomposition reaction Methods 0.000 claims description 2
- 230000015654 memory Effects 0.000 claims description 2
- 238000000537 electroencephalography Methods 0.000 description 49
- 230000000694 effects Effects 0.000 description 32
- 230000000638 stimulation Effects 0.000 description 28
- 210000004556 brain Anatomy 0.000 description 22
- 238000000034 method Methods 0.000 description 19
- 210000003128 head Anatomy 0.000 description 15
- 230000009467 reduction Effects 0.000 description 13
- 238000005259 measurement Methods 0.000 description 11
- 238000011156 evaluation Methods 0.000 description 9
- 238000001228 spectrum Methods 0.000 description 9
- 230000000007 visual effect Effects 0.000 description 9
- 230000007177 brain activity Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 238000009795 derivation Methods 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000013507 mapping Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000008092 positive effect Effects 0.000 description 4
- 238000010183 spectrum analysis Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 208000016354 hearing loss disease Diseases 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000002653 magnetic therapy Methods 0.000 description 3
- 210000001595 mastoid Anatomy 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 208000016621 Hearing disease Diseases 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000012076 audiometry Methods 0.000 description 2
- 238000012550 audit Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 210000000860 cochlear nerve Anatomy 0.000 description 2
- 238000013500 data storage Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000003027 ear inner Anatomy 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000000051 music therapy Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000010349 pulsation Effects 0.000 description 2
- 230000001020 rhythmical effect Effects 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000011491 transcranial magnetic stimulation Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- 206010011878 Deafness Diseases 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 101000934888 Homo sapiens Succinate dehydrogenase cytochrome b560 subunit, mitochondrial Proteins 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical group [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- 208000035286 Spontaneous Remission Diseases 0.000 description 1
- 102100025393 Succinate dehydrogenase cytochrome b560 subunit, mitochondrial Human genes 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 210000003984 auditory pathway Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 238000013542 behavioral therapy Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000003670 easy-to-clean Effects 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000004070 electrodeposition Methods 0.000 description 1
- 238000002571 electroretinography Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 230000004424 eye movement Effects 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000002599 functional magnetic resonance imaging Methods 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000002219 manual therapy Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000011328 necessary treatment Methods 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000036403 neuro physiology Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- MNKCCFOQDGJSLR-UHFFFAOYSA-N premycofactocin Chemical compound OC1=CC=C(C=C1)CC1C(C(C(N1)=O)=O)(C)C MNKCCFOQDGJSLR-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000000645 stria vascularis Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/389—Electromyography [EMG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/12—Audiometering
- A61B5/128—Audiometering evaluating tinnitus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F11/00—Methods or devices for treatment of the ears or hearing sense; Non-electric hearing aids; Methods or devices for enabling ear patients to achieve auditory perception through physiological senses other than hearing sense; Protective devices for the ears, carried on the body or in the hand
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N2/00—Magnetotherapy
- A61N2/004—Magnetotherapy specially adapted for a specific therapy
- A61N2/006—Magnetotherapy specially adapted for a specific therapy for magnetic stimulation of nerve tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N2/00—Magnetotherapy
- A61N2/02—Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7203—Signal processing specially adapted for physiological signals or for diagnostic purposes for noise prevention, reduction or removal
- A61B5/7207—Signal processing specially adapted for physiological signals or for diagnostic purposes for noise prevention, reduction or removal of noise induced by motion artifacts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N2/00—Magnetotherapy
- A61N2/002—Magnetotherapy in combination with another treatment
Definitions
- the tinnitus problem is therefore to be regarded as very complex, because the ear noises occur in different forms (duration, nature of the sound) and beyond the reaction of the affected person to the sounds is highly individual (from a mild disorder to the absolute unbearable.). So far, especially drug-based procedures and infusions are used, which usually only have a positive effect in the acute tinnitus stage.
- Other adjuncts include psychological procedures (e.g., behavioral therapy, education), acoustic masking (e.g., with a hearing aid noise generator), various methods of relaxation, and alternative methods such as exercise therapy. Electrostimulation established.
- the invention includes the development of a technically optimized diagnostic (Cermag) and therapy device (Certis) for tinnitus sufferers for the reduction or suppression / suppression of tinnitus noise based on the diagnostic (Cermag) and therapy device (Certis) for tinnitus sufferers for the reduction or suppression / suppression of tinnitus noise based on the diagnostic (Cermag) and therapy device (Certis) for tinnitus sufferers for the reduction or suppression / suppression of tinnitus noise based on the
- Cermag is based on a quantitative EEG (Q-EEG), where the derivation is limited to a few application-specific electrode types.
- Q-EEG quantitative EEG
- Electroencephalography With Q-EEG, the Fourier transform of the received signals is evaluated, thus making a spectral analysis.
- the low-field transcranial magnetic stimulation leads to a change in the Q-EEG signature dependent on frequency and direction.
- the therapy device Certis consists of a head and a base part. On the Headboard areas of the head, especially the inner ear, auditory nerve, auditory pathway, nuclei and parts of the brain and / or the spine or parts of the spine with a low-frequency electrical and / or
- Electromagnetic field stimulated in the frequency range determined by the Q-EEG via applicators iron core coils.
- This therapy device is also characterized by the fact that it provides not only the magnetic field stimulation signals but also a high-resolution playback unit for special purposes
- the therapy device also has a control unit. With the help of the control unit, the person concerned operates the device. Due to the product's features, the device enables people who are suffering from tinnitus to return to public professional and private life.
- the Certis device also has both a mobile protocoller storage medium and its own data storage medium for the individualized parameters.
- the head part - stimulator - consists of a "foam cube", in which the head is placed for the therapy.In the head part the stimulation coils (applicators) for the magnetic field are integrated.
- the derivation of the brain activity is carried out according to the international 10-20 system by means of an electrode cap (Electro Cap Co. USA).
- an electrode cap Electro Cap Co. USA
- silver chloride electrodes are used.
- the amplified and filtered analog signals are converted into digital signal sequences.
- the sample rate determines how often the analog signal is quantized per second.
- the digital signal sequences are stored continuously on a recording system.
- the records of the EEG data are stored in an electrically and soundproofed room.
- the examination is carried out with relaxed sitting in the chair subjects.
- the registration of the brain activity takes place under the conditions eyes open and eyes closed over a period of in each case at least 10 minutes. Over a period of at least 10 minutes, the registration of brain activity takes place under the conditions eyes open and eyes closed.
- Electrode artifacts that can occur when the scalp-to-electrode contact is unstable or the electrodes are poorly attached to the head) Affected epochs (visual inspection), the frequency analysis (Fast Fourier Transformation) over 19 real electrode positions using 2 s data epochs in real time.
- the representation of the EEG data is ultimately in the form of brain maps, power spectra and in numerical form.
- the statistical evaluation of the EEG data is done by means of the StatView program.
- the stored raw data can be subsequently converted into each reference assembly by means of corresponding differences and presented with an average reference. Based on the stored raw data, these transformations can subsequently be carried out arbitrarily and arbitrarily often with one and the same EEG section.
- the decomposition of the EEG into the classical frequency bands (2-4Hz (delta), 4-7Hz (Theta), 8-13 Hz (alpha), 14-21 Hz (beta), 22-64 Hz (gamma) in lhz bands, as well as Brain Maps rendering, allow visual presentation of information hidden in the background activity.
- tinnitus is audiometrically and psychometrically limited. Therefore, we asked us whether tinnitus can detect typical changes in the quantitative EEG and, if necessary, these changes can be used as the basis for a therapy application and to check its success.
- the calculation and representation as quantitative EEG shows the relative and absolute distribution of individual frequency spectra as brain mapping or as power spectrum.
- tinnitus patients Tinnitus-related changes in total energy and tinnitus-typical signals in their percentage frequency.
- the average total energy level was significantly reduced in male tinnitus patients compared to the control group, whereas it was significantly increased in female patients.
- the changes mainly affect the alpha and theta band, the delta band less, and the alpha and beta band in the female group.
- the data collected allowed a score to be generated on the basis of the percentage distribution, including the changes in overall power, to determine the likelihood of tinnitus.
- Neurofeedback as a treatment method that acts on the specific location-specific change of the frequency distribution pattern presupposes the exact knowledge of the typical tinnitus-related EEG changes.
- Successful neurofeedback can be seen in the quantitative EEG as well as in evaluation by tinnitus questionnaire according to Goebel and Hiller, by means of SCL90R questionnaire and BDI questionnaires.
- the low-field transcranial magnetic stimulation leads to a change in the EEG signature, dependent on frequency and direction. Their positive or negative impact is evidenced by a quantitative EEG study. Their success is verifiable as well as neurofeedback by quantitative EEG and questionnaire according to Goebel and Hiller, SCL90R questionnaire and BDI questionnaire.
- QEEG data allow therapies to be reviewed while at the same time providing the basis for the application of magnetic therapy or neurofeedback.
- they allow the application-related EEG diagnostics in tinnitus to limit the derivation of fewer types of electrodes.
- EEG data can be calculated and graphically displayed in the form of maps (EEG map or spectral parameter map).
- maps EEG map or spectral parameter map.
- the registration of the EEG's done according to the demand of the German Society for Clinical Neurophysiology with 19 positions of the 10-20 system and is stored electronically. After visual inspection, the FFT of the artifact-free EEG epochs takes place.
- the EEG data are presented in the form of brain maps, power spectra and numerics.
- the power values are calculated for the frequency ranges: Delta (0.5 - 4 Hz), Theta (4 - 7 Hz), Alpha (8 - 13 Hz) and Beta (14 - 21 Hz) and Gamma (22 - 64 Hz) , In Fig. 3 the effectiveness is illustrated by means of a case study:
- Sex male, age: 55 years, tinnitus duration: 38 months, tinnitus bilateral
- the associated brain map is shown graphically in FIG. 4, the power spectrum in FIG. 5.
- the computer - aided evaluation of the EEG data provided evidence that frequency - controlled magnetic fields induce frequency - dependent changes in the brain wave pattern of tinnitus patients.
- Tinnitus is detectable in the QEEG.
- FIGS. 8 and 9 show different effects (positive / negative) on the EEG of different persons.
- Tinnitus typical signals can be detected and are the prerequisite of an individual therapy. Tinnitus therapies are verifiable in their success with this diagnostic (FIG. 10).
- a field strength of 5 ⁇ T has been used successfully.
- the frequency of the pulsations is in particular between 1 and 100 Hz. This system allows us to individually control the frequency of the magnetic field.
- the effects of the pulsating magnetic fields are represented by means of a power spectrum, brain maps and a CSA.
- Beta 14-21 Hz low gamma (30 - 42 Hz)
- the goal is to develop objective diagnostic tests for tinnitus that are cost-effective, simple and fast.
- a stimulus such as a sound or sound
- brain waves oscillate at a frequency of 40 Hz. This is also referred to as gamma-band activity. This activity is only present during the excitation, ie during the sound or noise. If someone is constantly experiencing tinnitus, gamma-band activities should be constantly in the auditory area of the cortex. The louder the tinnitus, the higher auditory activity should be present.
- EEG device gamma-band measurements are made that objectively detect tinnitus in its presence and volume.
- a second effort is to observe brain activity using magnetic resonance imaging (fMRI) techniques and attempt to match the resulting magnetic resonance images to the presence and / or intensity of tinnitus.
- fMRI magnetic resonance imaging
- Tinnitus typical signals can be detected and are the prerequisite for individual therapy. Tinnitus therapies are verifiable in their success with this diagnostic. b. Therapy device Certis
- Copy protection Content not downloadable from the device, watermarking capable (Frauenhofer system), but no DRM 10-capable copy protection 13. Own data format! Data automatically deletes when the subscription expires
- Compliance control the frequency and timing of hearing can be determined retrospectively, the built-in meter can be used to log the monitoring of the music by day and hour, identification of patient parameters by means of which an individual adjustment of the device parameters can be made.
- the graphic display with a touchscreen overlay is very similar to a well-known "IPod.”
- the device is digitally protected except by disassembling the integrated memory chip on which the data is located, or by cutting the headphone cable (! Analog copy!), As no common interfaces for PC's are used and the data file format of music raw data is not a common file format.
- MicroSD card pluggable; File system FAT16 / 32 (PC compatible);
- microSD card for a log file (application times, duration, etc.)
- Microchip signal processor (dsPIC33F, up to 40MIPS)
- the operating software (hardware driver) is written in C (microchip compiler), with additional libraries.
- the operating time per battery pack can only be determined after practical tests; Expected to be reachable> 50h. Of course, compatible batteries can be used if required, since the voltage transformer from IV
- the SD card library is already enhanced for SDHC compatibility; With this, for example, with a 16GB microSD card, it is possible to record about 1200 minutes at 48kHz / stereo (there are also larger cards!). A headboard is designed to meet the specific needs of the application. The following points should be considered:
- the headboard will be able to adapt to the different head shapes and sizes. Due to the special construction of the head part, the applicator will be positioned much more accurately at the desired location, e.g. at the mastoid. However, during development it is possible to work out the possibility of stimulating other places on the head.
- the headboard must have a high wearing comfort. It should be tested, if a covering of the ears makes sense.
- BEAM Brain Electrical Activity Mapping
- FIGS. 12-17 show further possible head part developments.
- Fig. 12 shows: The entire headband is equipped with a snap button strip.
- the therapy element is attached to the ideal height on the bracket and can also be extended in the longitudinal direction.
- Fig. 13 shows:
- the headband is a rail system with several locking positions on which the therapy element can be vertically adjusted in height.
- the therapy element can also be pushed apart horizontally and thus extended to achieve the ideal site of action on the head.
- Fig. 14 shows: A transverse bar with the two therapy elements is attached to a headband with a rail system.
- the bracket along the rail can be moved vertically and the therapy elements themselves can be pushed horizontally along the crossbar to the appropriate position.
- Both headband and crossbar can be resized.
- Fig. 15 shows: The two therapy elements are attached to the right and left of an elastic headband. The elements can go along one attached to the headband outside loop at several positions.
- Fig. 16 shows: The two therapy elements are located on the right and left within an elastic headband.
- the headband can be opened on the inside to hang the elements in different positions.
- Fig. 17 shows: The therapy element is attached to an ear clip, which is placed outside on the auricle.
- the bobbin case is attached to a pivotable arm for vertical adjustment.
- the arm is also extendable for horizontal position adjustment.
- the new device will be operable via three "push-buttons", the functions are visible on an LCD display.
- Menu navigation There will be several programs to choose from. The control menu will perform the user.
- Timer & Compliance Monitor Time recording and control system for reminder and easy use, with the aim of reducing the times to the minimum necessary. Identification of patient parameters by means of which an individual adaptation of the device parameters can be made.
- Design A functional-aesthetic design is designed to increase the technical competence and credibility of the device.
- Packaging A combination of suitable transport packaging with a product packaging (such as a casket) that is optimal for the therapy program will be used.
- rhythmic sound of the drum is a fundamental instrument for triggering and maintaining the shamanic state of consciousness. Examining the effect of regular, monotonous drumbeat on EEG patterns, researcher Andrew Neher noted that rhythmic beats dramatically alter brainwave activity. Other observers of shamanic rituals have found that drumming frequencies in the theta range prevailed during initiation rites.
- Low-frequency deep stimulation is more sustainable and can lead to therapeutic effects.
- One of the decision criteria should be the audiogram, but if the person has no serious hearing loss, then what? Do you then take notes from the tactile area or do you focus on what is pleasing to the patient or whether the offered music, which underlies the notes, does not bother too much?
- the remedy is an otoacoustic measurement.
- the therapy device and the diagnostic device can use all possible stimulation signal patterns to optimize the QEEG results, especially in electromagnetic or electrical stimulation. There are no limitations on the desired and possible waveform that can be used to stimulate.
- the protection of the Certis & Cermag system also includes the evaluation and optimization by QEEG of all other different stimulation methods known to us, e.g. also audiovisual or visual, thermal, with laser & vibrating systems stimulation optimization enabled with Certis & Cermag.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Acoustics & Sound (AREA)
- Medical Informatics (AREA)
- Radiology & Medical Imaging (AREA)
- Surgery (AREA)
- Audiology, Speech & Language Pathology (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Multimedia (AREA)
- Otolaryngology (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Magnetic Treatment Devices (AREA)
Abstract
L'invention porte sur un dispositif pour le traitement des acouphènes à l'aide d'un appareil EEG, en particulier d'un appareil Q-EEG, ainsi qu'une partie de tête, qui comprend au moins un applicateur, lequel produit un champ magnétique basse fréquence dans la gamme de fréquence de 1 à 100 Hz, pour une intensité du champ inférieure à 20 mT.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102009034491 | 2009-07-22 | ||
| PCT/EP2010/060256 WO2011009807A1 (fr) | 2009-07-22 | 2010-07-15 | Dispositif de traitement des acouphènes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP2456350A1 true EP2456350A1 (fr) | 2012-05-30 |
Family
ID=42988469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP10730812A Withdrawn EP2456350A1 (fr) | 2009-07-22 | 2010-07-15 | Dispositif de traitement des acouphènes |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20120203130A1 (fr) |
| EP (1) | EP2456350A1 (fr) |
| WO (1) | WO2011009807A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4417247A1 (fr) | 2023-02-15 | 2024-08-21 | VV Analytics | Système et procédé de traitement d'acouphène par biorésonance |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102139140A (zh) * | 2011-04-27 | 2011-08-03 | 华南理工大学 | 带声乐功能的经颅微电流刺激器 |
| US20140058189A1 (en) * | 2012-02-20 | 2014-02-27 | William F. Stubbeman | Systems and methods using brain stimulation for treating disorders |
| US9031631B2 (en) | 2013-01-31 | 2015-05-12 | The Hong Kong Polytechnic University | Brain biofeedback device with radially adjustable electrodes |
| WO2014139029A1 (fr) * | 2013-03-15 | 2014-09-18 | Neurogate Medical Systems Inc. | Dispositif et procédé de positionnement d'une bobine de stimulation magnétique transcrânienne avec intégration de données. |
| CN103239237B (zh) * | 2013-04-27 | 2015-06-24 | 江苏贝泰福医疗科技有限公司 | 耳鸣诊断测试装置 |
| CN103494669B (zh) * | 2013-04-27 | 2015-10-07 | 江苏贝泰福医疗科技有限公司 | 耳鸣治疗装置 |
| DE102013211859B4 (de) * | 2013-06-21 | 2015-07-16 | Technische Universität München | Magnetstimulator zur Stimulation eines Gewebes durch ein Magnetfeld |
| US20150097553A1 (en) * | 2013-10-04 | 2015-04-09 | The Mind App Ltd Oy | Device and method for measuring very low frequency electromagnetic fields |
| EP3928827A1 (fr) | 2014-12-31 | 2021-12-29 | Stimwave Technologies Incorporated | Ensemble antenne |
| KR101747958B1 (ko) * | 2015-04-07 | 2017-06-15 | 주식회사 디알메디칼 | 귀속 치료 장치 및 귀속 치료 장치의 구동 방법 |
| WO2017106884A1 (fr) * | 2015-12-23 | 2017-06-29 | Gerald Neuwirth | Dispositif servant à générer des champs magnétiques alternatifs afin d'induire des courants de foucault dans un organisme |
| AT518114B1 (de) * | 2015-12-23 | 2017-11-15 | Neuwirth Gerald | Vorrichtung zur Erzeugung von magnetischen Wechselfeldern zum Induzieren von Wirbelströmen in einem Organismus |
| CN109862938A (zh) * | 2016-07-29 | 2019-06-07 | 氦3资源有限公司 | 一种听力损失缓解装置及使用该装置的方法 |
| CA3038822A1 (fr) | 2016-09-29 | 2018-04-05 | Mindset Innovation, Inc. | Casque d'ecoute destine a la surveillance de signaux biologiques |
| CN110114115B (zh) * | 2016-10-25 | 2023-06-06 | 脑路有限公司 | 用于预测治疗结果的设备及方法 |
| US11723579B2 (en) | 2017-09-19 | 2023-08-15 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement |
| WO2019069175A1 (fr) * | 2017-10-05 | 2019-04-11 | Cochlear Limited | Correction de distraction au niveau d'une prothèse auditive |
| US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
| US11478603B2 (en) | 2017-12-31 | 2022-10-25 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
| US12280219B2 (en) | 2017-12-31 | 2025-04-22 | NeuroLight, Inc. | Method and apparatus for neuroenhancement to enhance emotional response |
| US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
| WO2020056418A1 (fr) | 2018-09-14 | 2020-03-19 | Neuroenhancement Lab, LLC | Système et procédé d'amélioration du sommeil |
| WO2020188415A1 (fr) | 2019-03-18 | 2020-09-24 | Cochlear Limited | Système et procédé de suppression des acouphènes |
| US11786694B2 (en) | 2019-05-24 | 2023-10-17 | NeuroLight, Inc. | Device, method, and app for facilitating sleep |
| CN113456087A (zh) * | 2021-08-18 | 2021-10-01 | 乔月华 | 一种基于神经生物反馈疗法的耳鸣诊疗系统及其使用方法 |
| EP4499007A1 (fr) * | 2022-03-31 | 2025-02-05 | St Oto Devices, LLC | Appareil et procédés de traitement des acouphènes |
| EP4470606A1 (fr) * | 2023-05-30 | 2024-12-04 | Gbo Medizintechnik AG | Dispositif applicateur pour appliquer des champs magnétiques pour une thérapie par champ magnétique |
| DE102023133292A1 (de) * | 2023-11-28 | 2025-05-28 | Armin Bernhard | Anordnung zur Verwendung bei der Behandlung von Demenz, Depression, HRV-Regulation, Morbus Raynaud, Asperger-Syndrom, Migräne, Schwindel, Schlafstörung, Burn-Out, ADHS, muskulären und/oder Gelenkschmerzen oder Autismus |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0537385A1 (fr) * | 1991-10-14 | 1993-04-21 | DORN GmbH | Appareil destiné à la thérapie du bourdonnement d'oreille |
| US7460903B2 (en) * | 2002-07-25 | 2008-12-02 | Pineda Jaime A | Method and system for a real time adaptive system for effecting changes in cognitive-emotive profiles |
| WO2005124722A2 (fr) * | 2004-06-12 | 2005-12-29 | Spl Development, Inc. | Systeme de reeducation auditive et son procede d'utilisation |
| US20090099474A1 (en) * | 2007-10-01 | 2009-04-16 | Pineda Jaime A | System and method for combined bioelectric sensing and biosensory feedback based adaptive therapy for medical disorders |
-
2010
- 2010-07-15 WO PCT/EP2010/060256 patent/WO2011009807A1/fr not_active Ceased
- 2010-07-15 EP EP10730812A patent/EP2456350A1/fr not_active Withdrawn
- 2010-07-15 US US13/386,298 patent/US20120203130A1/en not_active Abandoned
Non-Patent Citations (1)
| Title |
|---|
| See references of WO2011009807A1 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4417247A1 (fr) | 2023-02-15 | 2024-08-21 | VV Analytics | Système et procédé de traitement d'acouphène par biorésonance |
| WO2024170425A1 (fr) | 2023-02-15 | 2024-08-22 | Vv Analytics | Système et procédé de traitement de l'acouphène par biorésonance |
Also Published As
| Publication number | Publication date |
|---|---|
| US20120203130A1 (en) | 2012-08-09 |
| WO2011009807A1 (fr) | 2011-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2456350A1 (fr) | Dispositif de traitement des acouphènes | |
| EP3188794B1 (fr) | Dispositif de neurostimulation non effractive au moyen de rafales multicanaux | |
| US20250194994A1 (en) | System and method for characterizing brain states during general anesthesia and sedation using phase-amplitude modulation | |
| EP2887861B1 (fr) | Appareil pour étudier une distribution de phases pour identifier une interaction pathologique entre différentes régions du cerveau | |
| US10933213B2 (en) | Device and method for hearing threshold-adapted acoustic stimulation | |
| Dimitrijevic et al. | Cortical alpha oscillations predict speech intelligibility | |
| Bertoli et al. | Temporal resolution in young and elderly subjects as measured by mismatch negativity and a psychoacoustic gap detection task | |
| Paus et al. | Synchronization of neuronal activity in the human primary motor cortex by transcranial magnetic stimulation: an EEG study | |
| Castro et al. | Coherent neocortical 40‐Hz oscillations are not present during REM sleep | |
| Uppenkamp et al. | Human auditory neuroimaging of intensity and loudness | |
| US20150105837A1 (en) | Brain therapy system and method using noninvasive brain stimulation | |
| Tognola et al. | Wavelet analysis of click-evoked otoacoustic emissions | |
| WO2002062264A2 (fr) | Therapie basee sur des sons asservis par eeg, destinee aux acouphenes | |
| Ruhnau et al. | Flicker-driven responses in visual cortex change during matched-frequency transcranial alternating current stimulation | |
| Won et al. | Relationship between behavioral and physiological spectral-ripple discrimination | |
| Walker et al. | Linking cortical spike pattern codes to auditory perception | |
| Bertoli et al. | Novel sounds as a psychophysiological measure of listening effort in older listeners with and without hearing loss | |
| Daud et al. | Effect of audiovisual stimulation on adult memory performance based electroencephalography wavelet analysis | |
| Wable et al. | Mismatch negativity: a tool for the assessment of stimuli discrimination in cochlear implant subjects | |
| Cardon | Somatosensory cross-modal reorganization in children with cochlear implants | |
| Heinze et al. | Prior knowledge changes initial sensory processing in the human spinal cord | |
| Ginnan | Deprivation-Induced Plasticity of the Auditory Pathway | |
| Wang et al. | Visual Information Affects Auditory Frequency Discrimination with Random Stimulus Sequences: Evidence from ERPs | |
| BERUMEN SALAZAR | Steady state visual evoked potentials and the visual perception curve | |
| Patel | A real time frequency analysis of the electroencephalogram using labview |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20120222 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
| DAX | Request for extension of the european patent (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20170201 |